Precision BioSciences prices $125M stock offering at $7.75 - Investing.com
Investing.com · Nov 5, 12:42 PM
Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Business Wire
Business Wire · Nov 5, 12:10 PM
Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure - Business Wire
Business Wire · Nov 5, 12:00 PM
Market reactionShares rose 22% on Nov 5.
Precision BioSciences is a clinical-stage company developing in vivo ARCUS gene editing therapies, led by PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy; none is approved.
Precision's case rests on PBGENE-HBV eliminating the cccDNA that sustains chronic hepatitis B. Phase 1 biopsy and durable pgRNA results support that mechanism, while sustained viral suppression off antivirals remains the key clinical goal. PBGENE-DMD adds a second clinical opportunity, with initial safety data targeted for year-end 2026 and efficacy updates expected in H1 and H2 2027. Management expects funding through 2028, conditional on operating discipline and availability of its at-the-market facility.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: pgRNA loss stays durable
Does pgRNA loss remain durable in both HBeAg-positive and HBeAg-negative patients, with additional biopsy support?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
HBV durability update approaches; DMD safety remains the next portfolio milestone
First-ever clinical cccDNA elimination in HBV sets Precision apart, but Phase 2 cure data will determine whether gene editing becomes a functional cure standard
First clinical proof of cccDNA elimination in hepatitis B positions PBGENE-HBV as the lead asset, contingent on whether Phase 2 sustains functional cure signals
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Blood cancers, Neuromuscular diseases, Neurology and pain, Infectious diseases, Rare genetic and metabolic diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
24 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.